Vertex Pharmaceuticals is set to post its third-quarter results next month, and analysts project a single-digit earnings drop ...

Learn about the current medication options for managing type 2 diabetes and chronic kidney disease, including SGLT2 ...

Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease ...

The NHS has announced that newborns will be screened for a rare, life-threatening metabolic disorder that can lead to kidney ...

A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease — a ...

Indeed, simple liver cysts are almost always asymptomatic and found incidentally during routine testing for something else. These masses are not cancerous and not even dangerous. Simple cysts of the ...

Bryce Vissel does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

A gene therapy injected into patients’ brains slowed progression of the disease by 75 percent, preliminary findings reported. By Dana G. Smith Preliminary results from a small clinical trial to treat ...

“Our pursuit of breakthrough science and serial innovation has changed the treatment landscape for cystic fibrosis ... the onset of end-stage kidney disease or death. The final study analysis will ...

Please provide your email address to receive an email when new articles are posted on . Estimated glomerular filtration rate prior to cisplatin treatment predicted who had higher risk for chronic ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle ...